SCHEMBL3146239

SCHEMBL3146239

[CH2]CCc1ccc(C2CCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 3/20 0.41
PTGES2 Q9H7Z7 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
HAO1 Q9UJM8 1/20 0.38
ESR2 Q92731 6/20 0.37
ESR1 P03372 5/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
NAAA Q02083 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544467 0.98 SPHK1 (0.40) SPHK1PTGES2HDAC1HDAC8HDAC6
SCHEMBL7652663 0.88 SPHK1 (0.46) SPHK1PTGES2CYP3A4CYP2D6FFAR4
SCHEMBL7650177 0.86 SPHK1 (0.45) SPHK1HTR2CHTR2BFFAR4
SCHEMBL7654715 0.86 SPHK1 (0.49) SPHK1CYP3A4CYP2D6FFAR4
SCHEMBL7651816 0.85 SPHK1 (0.47) SPHK1CYP3A4CYP2D6FFAR4
SCHEMBL7650285 0.85 SPHK1 (0.51) SPHK1CYP3A4CYP2D6FFAR4
SCHEMBL7647363 0.83 SPHK1 (0.50) SPHK1FFAR4
SCHEMBL676292 0.83 HDAC8 (0.41) HDAC1HDAC8HDAC6HTR2CHTR2B
SCHEMBL676977 0.81 HAO1 (0.42) HDAC1HDAC8HDAC6HTR2CHTR2B
SCHEMBL330369 0.81 HAO1 (0.42) HDAC1HDAC8HDAC6HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104205472-B Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same 三菱化学株式会社 2017-04-12 CN disclosed
CN-104205472-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEM CORP 2014-12-10 CN disclosed
EP-1565430-B1 BIGUANIDE DERIVATIVES JACOBUS PHARMA CO INC (US) 2010-02-17 EP disclosed
US-7563792-B2 Biguanide and dihydrotriazine derivatives JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2009-07-21 US disclosed
US-20080176852-A1 BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES JACOBUS PHARMACEUTICAL COMPANY, INC. 2008-07-24 US disclosed
US-7256218-B2 Biguanide and dihydrotriazine derivatives JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2007-08-14 US disclosed
EP-1565430-A1 BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES JACOBUS PHARMACEUTICAL CO. INC. (US) 2005-08-24 EP disclosed
US-20040116428-A1 Biguanide and dihydrotriazine derivatives JACOBUS PHARMACEUTICAL COMPANY, INC. 2004-06-17 US disclosed
WO-2004048320-A1 BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES JACOBUS PHARMACEUTICAL COMPANY, INC. (US) 2004-06-10 WO disclosed
CN-1149214-C Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient ������������ʽ���� 2004-05-12 CN disclosed
US-6492364-B1 Triazolo and derivatives as chemokine inhibitors TORAY INDUSTRIES, INC. (JP) 2002-12-10 US disclosed
CN-1293674-A Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient TORAY INDUSTRIES (JP) 2001-05-02 CN disclosed
EP-1067130-A1 TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT TORAY INDUSTRIES, INC. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176852-A1 BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES QDPR, DHODH, GLMN SPHK1 1162/4885PTGES2 2056/4885HDAC1 2577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.